Try Alerts Free   |   Login
Health Care › Services-Medical Laboratories

Miragen Therapeutics (MGEN) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 26 quarters since 2015. Compare with MGEN stock chart to see long term trends.

MGEN stock compared to

MGEN Income Statement

Revenue, Net:1090000
Revenue Per Share:0.11
Research & Development Expense:12565000
Total Operating Expenses:19088000
Operating Income:-17998000
Net Income:-17964000
Earnings Per Share, Basic:-2.21
Shares Outstanding, Basic Avg:9587155

MGEN Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:25000
Change in Accounts Receiveable:null
Net Cash from Operations:-14631000
Net Cash from Financing Activities:7052000
Property, Plant & Equipment Purchases:54000
Net Cash from Investing Activities:-11205000
Net Change in Cash & Equivalents:-18784000

MGEN Balance Sheet

Cash and Cash Equivalents:109300000
Short-Term Investments:81597000
Accounts Receivable, Net:null
Total Current Assets:115462000
Property, Plant & Equipment, Net:298000
Total Assets:118202000
Accounts Payable:2392000
Total Short-Term Liabilities:16830000
Total Liabilities:19290000

Insider Trading

Change
Value
Transaction
SEC Form 4
Frazier Life Sciences Public Fund, L.P.   10% Owner
200,000 sh at $11
$2,200,000
Buy
Fairmount Funds Management LLC   Director and 10% Owner
 
 
Buy

Data imported from Miragen Therapeutics Inc SEC filings. Check original filings before making any investment decision.